Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats

Behavioural Brain Research

Volumn 262, Issue , 2014, Pages 1-7

  Ouachikh, Omar ^a   Dieb, Wisam ^a   Durif, Franck ^a,b   Hafidi, Aziz ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

6 OHDA; Conditioned place preference; Parkinson; Reward

Indexed keywords

BROMOCRIPTINE; COCAINE; DOPAMINE; PRAMIPEXOLE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR VENTRAL TEGMENTAL; ARTICLE; BRAIN DAMAGE; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; MALE; MOTIVATION; NEUROANATOMY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REINFORCEMENT; SHAM PROCEDURE; VENTRAL TEGMENTUM;

6-OHDA; CONDITIONED PLACE PREFERENCE; PARKINSON; REWARD;

ANIMALS; BENZOTHIAZOLES; BROMOCRIPTINE; COCAINE; CONDITIONING (PSYCHOLOGY); DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; MALE; MOTIVATION; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; VENTRAL TEGMENTAL AREA;

EID: 84892505709     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.12.021     Document Type: Article

References (46)

1. Bordet R. Central dopamine receptors: general considerations (Part 1). Rev Neurol (Paris) 2004, 160:862-870.
2. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 1991, 564:203-219.
3. Breese G.R., Taylor T.D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 1971, 42:88-99.
4. Carlezon W.A., Kosten T.A., Nestler E.J. Behavioral interactions caused by combined administration of morphine and MK-801 in rats. Psychopharmacology (Berl) 2000, 151:261-272.
5. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000, 20:3864-3873.
6. Chen N.N., Pan W.H. Regulatory effects of D2 receptors in the ventral tegmental area on the mesocorticolimbic dopaminergic pathway. J Neurochem 2000, 74:2576-2582.
7. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
8. Diaz J., Pilon C., LeFoll B., Gros C., Triller A., Schwartz J.C., et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000, 20:8677-8684.
9. Ding Z.M., Liu W., Engleman E.A., Rodd Z.A., McBride W.J. Differential effects of dopamine D2 and GABA(A) receptor antagonists on dopamine neurons between the anterior and posterior ventral tegmental area of female Wistar rats. Pharmacol Biochem Behav 2009, 92:404-412.
10. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009, 24:1561-1570.
11. Fenu S., Wardas J., Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol 2009, 20:363-379.
12. German D.C., Manaye K.F. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J Comp Neurol 1993, 331:297-309.
13. Haber S.N., Fudge J.L., McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000, 20:2369-2382.
14. Hemby S.E., Jones G.H., Neill D.B., Justice J.B. 6-Hydroxydopamine lesions of the medial prefrontal cortex fail to influence cocaine-induced place conditioning. Behav Brain Res 1992, 49:225-230.
15. Huston J.P., Silva M.A., Topic B., Müller C.P. What's conditioned in conditioned place preference. Trends Pharmacol Sci 2013, 34:162-166.
16. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 2007, 56:27-78.
17. Ito R., Robbins T.W., Everitt B.J. Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nat Neurosci 2004, 7:389-397.
18. Jankovic J., Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol 2012, 25:433-447.
19. Kauer J.A., Malenka R.C. Synaptic plasticity and addiction. Nat Rev Neurosci 2007, 8:844-858.
20. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
21. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 2009, 20:1-17.
22. Le Moine C., Bloch B. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 1996, 73:131-143.
23. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers A. Paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A 1995, 92:1719-1723.
24. Limotai N., Oyama G., Go C., Bernal O., Ong T., Moum S.J., et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci 2012, 122:145-153.
25. Margolis E.B., Mitchell J.M., Ishikawa J., Hjelmstad G.O., Fields H.L. Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. J Neurosci 2008, 28:8908-8913.
26. Nestler E.J. Is there a common molecular pathway for addiction?. Nat Neurosci 2005, 8:1445-1449.
27. Olson V.G., Zabetian C.P., Bolanos C.A., Edwards S., Barrot M., Eisch A.J., et al. Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci 2005, 25:5553-5562.
28. O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009, 23:157-170.
29. Ouachikh O., Dieb W., Durif F., Hafidi A. Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. Behav Brain Res 2013, 252:24-31.
30. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, New York.
31. Pickel V.M., Chan J., Nirenberg M.J. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions. Synapse 2002, 45:113-124.
32. Pioli E.Y., Meissner W., Sohr R., Gross C.E., Bezard E., Bioulac B.H. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008, 153:1213-1224.
33. Roberts D.C., Koob G.F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav 1982, 17:901-904.
34. Rodd Z.A., Bell R.L., Kuc K.A., Zhang Y., Murphy J.M., McBride W.J. Intracranial self-administration of cocaine within the posterior ventral tegmental area of Wistar rats: evidence for involvement of serotonin-3 receptors and dopamine neurons. J Pharmacol Exp Ther 2005, 313:134-145.
35. Rodd-Henricks Z.A., McKinzie D.L., Crile R.S., Murphy J.M., McBride W.J. Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats. Psychopharmacology (Berl) 2000, 149:217-224.
36. Rodd-Henricks Z.A., McKinzie D.L., Li T.K., Murphy J.M., McBride W.J. Cocaine is self-administered into the shell but not the core of the nucleus accumbens of Wistar rats. J Pharmacol Exp Ther 2002, 303:1216-1226.
37. Rogers D.C., Martel F.L., Dunnelt S.B. Nigral grafts in neonatal rats protect from aphagia induced by subsequent adult 6-OHDA lesions: the importance of striatal location. Exp Brain Res 1990, 80:172-176.
38. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
39. Schwarz S.S., Freed W.J. Brain tissue transplantation in neonatal rats prevents a lesion-induced syndrome of adipsia, aphagia and akinesia. Exp Brain Res 1987, 65:449-454.
40. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 1982, 9:321-353.
41. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001, 63:241-320.
42. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007, 12:227-462.
43. Voon V., Mehta A.R., Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 2011, 24:324-330.
44. Weiner D.M., Levey A.I., Sunahara R.K., Niznik H.B., O'Dowd B.F., Seeman P., et al. D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A 1991, 88:1859-1863.
45. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94:469-492.
46. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008, 14:169-183.